Free tool
Rare disease stocks
We cover 27 companies grouped under the Rare disease theme. The median market value in the group is $1.40B. Across the group, the median move over the past trading day is +0.15%. 56% of the 25 with a 200-day average trade above it. Price change over the past year runs from −29.1% to +266.0% across the middle 80 percent of the group, with a median of +6.8%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
27 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| VX1.DE | Vertex Pharmaceuticals Incorporated | $139.82B | Large cap | +41.64% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $112.52B | Large cap | +40.77% |
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | $35.05B | Large cap | −46.60% |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | $32.28B | Large cap | −10.21% |
| 0JAV.L | Insmed Incorporated | $12.89B | Large cap | −7.52% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | $12.57B | Large cap | +1.80% |
| 0JDI.L | Ionis Pharmaceuticals, Inc. | $10.40B | Large cap | +47.26% |
| ABVX.PA | ABIVAX Société Anonyme | $10.21B | Large cap | +48.91% |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $9.93B | Mid cap | +15.03% |
| 0HI3.L | Arrowhead Pharmaceuticals, Inc. | $6.98B | Mid cap | +294.59% |
| CAMX.ST | Camurus AB (publ) | $3.79B | Mid cap | −15.35% |
| 0RD1.L | Camurus AB (publ) | $2.84B | Mid cap | −15.10% |
| 0L35.L | Sarepta Therapeutics, Inc. | $1.69B | Small cap | −0.06% |
| 0LIF.L | Ultragenyx Pharmaceutical Inc. | $1.40B | Small cap | −13.39% |
| 0HB0.L | Agios Pharmaceuticals, Inc. | $1.19B | Small cap | −13.00% |
| DBV.PA | DBV Technologies S.A. | $901.25M | Small cap | +60.13% |
| GNFT.PA | Genfit S.A. | $830.56M | Small cap | +310.45% |
| 0QNA.L | Basilea Pharmaceutica AG | $762.45M | Small cap | +41.96% |
| AYJ.DE | Valneva SE | $619.77M | Small cap | −21.89% |
| 0KBU.L | Omeros Corporation | $575.28M | Small cap | +332.86% |
| 0OB3.L | Valneva SE | $270.41M | Small cap | −25.05% |
| XUP.DE | Genfit S.A. | $258.22M | Small cap | +166.82% |
| 0QN1.L | Santhera Pharmaceuticals Holding AG | $254.58M | Small cap | +11.86% |
| 0T6G.L | Q32 Bio Inc. | $246.69M | Small cap | — |
| 0AB6.L | Hyloris Pharmaceuticals SA | $185.32M | Small cap | −33.23% |
| CRNO-B.ST | Cereno Scientific AB (publ) | $148.23M | Small cap | −53.59% |
| 0H8T.L | Aclaris Therapeutics, Inc. | $122.82M | Small cap | +237.38% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.